Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute. - Report - MDSpire

Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute.

  • By

  • May 21, 2026

  • 3 min

Share

Clinical Report: Transforming Urologic Care in Philadelphia and Worldwide

Overview

The Fox Chase – Temple Urologic Institute combines expertise from two leading institutions to provide a comprehensive range of urologic services, including advanced surgical options and clinical trials. It is recognized for its high surgical volumes in kidney and bladder cancer.

Background

The Fox Chase – Temple Urologic Institute merges the strengths of an NCI-designated Comprehensive Cancer Center and a leading academic health system.

Data Highlights

The Institute is ranked #1 in Pennsylvania for kidney cancer and bladder cancer surgical volumes.

Key Findings

  • Offers a broad range of surgical options including robotics and focal therapy.
  • Hosts one of the largest bladder preservation programs in the country.
  • Conducts innovative clinical trials such as INSITE and GAIN-BCG.
  • Utilizes the R.E.N.A.L Nephrometry score for categorizing renal masses.

Clinical Implications

The integration of advanced surgical techniques and clinical trials at the Fox Chase – Temple Urologic Institute provides healthcare professionals with access to treatment options for urologic conditions.

Conclusion

The Fox Chase – Temple Urologic Institute combines specialized expertise and innovative research.

Related Resources & Content

  1. Temple Health, Fox Chase-Temple Urologic Institute: The Next Generation of Urology Care
  2. Fox Chase Cancer Center, Connecting Across Continents: From Philadelphia to Kigali
  3. Fox Chase Cancer Center, International Kidney Cancer Collaboration with Leadership from Philadelphia
  4. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR)
  5. EAU Guidelines on Prostate Cancer - TREATMENT
  6. temple health — Benign Prostatic Hyperplasia
  7. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial - PubMed
  8. EAU Guidelines on Prostate Cancer - TREATMENT
  9. American Urological AssociationGuideline Amendment

Original Source(s)

Related Content